obinutuzumab,zanubrutinib
beigene,roche,biogen
['obinu', 'zanubrutinib', 'follicular', 'lymsm', 'gi ', 'rosewood', 'lymphoma']
congress #eha22 | pier luigi zinzani, university of bologna presented results from rosewood phase ii study of zanubrutinib+obinutuzumab in pts with r/r follicular lymphoma. n=217, orr=68.3, cr rate=37.2%, dor=70.9, median pfs=27.4 months, #lymsm #lymphoma 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm